Combination Treatment with Free Doxorubicin and Inductive Moderate Hyperthermia for Sarcoma Saos-2 Cells

Скорочена інформація про документ
dc.contributor.authorOrel, Valerii E.
dc.contributor.authorDiedkov, Anatolii G.
dc.contributor.authorOstafiichuk, Vasyl V.
dc.contributor.authorLyalkin, Sergii A.
dc.contributor.authorTkachenko, Igor O.
dc.contributor.authorKolesnyk, Denys L.
dc.contributor.authorOrel, Valerii B.
dc.contributor.authorDasyukevich, Olga Yo.
dc.contributor.authorRykhalskyi, Oleksandr Yu.
dc.contributor.authorMovchan, Oleksii V.
dc.contributor.authorGalkin, Alexander Yu.
dc.contributor.authorProsvietova, Anna B.
dc.date.accessioned2026-05-13T12:24:55Z
dc.date.available2026-05-13T12:24:55Z
dc.date.issued2025
dc.description.abstractBackground: Osteosarcoma (OS) is the most common primary malignant bone tumor. Doxorubicin (DOX) is extensively used in OS chemotherapy, yet improving patient outcomes remains challenging. This study investigated the effect of free DOX combined with inductive moderate hyperthermia (IMH) on Saos-2 human OS cells. Methods: Cell viability was assessed by trypan blue exclusion. Flow cytometry analyzed apoptosis, necrosis, and reactive oxygen species (ROS) in cells exposed to control (no treatment), IMH (42 MHz frequency, 500 µT magnetic field induction, 564 V/m electric field strength, 15 W output power, and 30 min duration) alone, DOX (0.06 µg/mL) alone, or DOX combined with IMH. The expression of p14ARF tumor suppressor and epidermal growth factor receptor (EGFR) was evaluated by immunocytochemistry. Spatial autocorrelation analysis quantified the heterogeneity of p14ARF and EGFR distributions in acquired images. Results: The half maximal inhibitory concentration (IC50) of DOX in Saos-2 cells had minimal variation between 48 h (0.060 ± 0.01 µg/mL) and 72 h (0.055 ± 0.003 µg/mL). DOX + IMH resulted in a 15% increase in early apoptosis and a 20% elevation in ROS levels compared with DOX alone. Immunocytochemical analysis revealed a 37% increase in p14ARF and a 32% reduction in EGFR expression following combined treatment in comparison to DOX alone. Image analysis showed that DOX + IMH treatment caused the highest Moran’s index values for p14ARF and EGFR, reflecting less heterogeneous spatial distributions (p < 0.05). Conclusions: IMH enhanced DOX-induced cytotoxicity in Saos-2 cells by initiating ROS-mediated apoptosis and reducing heterogeneity of cellular responses.
dc.format.pagerangeP. 852
dc.identifier.citationCombination treatment with free doxorubicin and inductive moderate hyperthermia for sarcoma saos-2 cells [Electronic resource] / Valerii E. Orel, Anatolii G. Diedkov, Vasyl V. Ostafiichuk, Sergii A. Lyalkin, Igor O. Tkachenko, Denys L. Kolesnyk, Valerii B. Orel, Olga Yo. Dasyukevich, Oleksandr Yu. Rykhalskyi, Oleksii V. Movchan, Alexander Yu. Galkin, Anna B. Prosvietova // Pharmaceuticals. — 2025. — Vol. 18, № 6. — P. 852. — Bibliogr.: 79 ref. — Title from screen.
dc.identifier.doihttps://doi.org/10.3390/ph18060852
dc.identifier.urihttps://ela.kpi.ua/handle/123456789/80852
dc.language.isoen
dc.relation.ispartofPharmaceuticals, 2025, Vol. 18, № 6
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectosteosarcoma
dc.subjectfree doxorubicin
dc.subjectinductive moderate hyperthermia
dc.subjectantitumor effect
dc.subjectreactive oxygen species
dc.subjectp14ARF
dc.subjectepidermal growth factor receptor
dc.subjecttumor cell heterogeneity
dc.titleCombination Treatment with Free Doxorubicin and Inductive Moderate Hyperthermia for Sarcoma Saos-2 Cells
dc.typeArticle

Файли

Контейнер файлів
Зараз показуємо 1 - 1 з 1
Ескіз
Назва:
pharmaceuticals-18-00852-v2.pdf
Розмір:
5 MB
Формат:
Adobe Portable Document Format
Завантажити
Ліцензійна угода
Зараз показуємо 1 - 1 з 1
Ескіз недоступний
Назва:
license.txt
Розмір:
8.98 KB
Формат:
Item-specific license agreed upon to submission
Опис:
Завантажити

Зібрання

Статті (ТМБ)